SCHEMBL3751817

SCHEMBL3751817

CCCCCCCC/C=C\CCCCCCCCOC(C)O

nearest known ligand 0.66

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.57
CNR1 P21554 1/20 0.57
CNR2 P34972 1/20 0.57
LPAR2 Q9HBW0 3/20 0.51
LPAR3 Q9UBY5 3/20 0.51
LPAR1 Q92633 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11877146 1.00 ALDH1A1 (0.57) ALDH1A1CNR1CNR2LPAR2LPAR3
SCHEMBL10882065 0.88 DNM1 (0.50) LPAR2LPAR3LPAR1
SCHEMBL10878345 0.88 DNM1 (0.50) LPAR2LPAR3LPAR1
SCHEMBL28358020 0.88 DNM1 (0.50) LPAR2LPAR3LPAR1
SCHEMBL1096441 0.88 DNM1 (0.50) LPAR2LPAR3LPAR1
SCHEMBL5537012 0.88 DNM1 (0.50) LPAR2LPAR3LPAR1
SCHEMBL6945069 0.88 DNM1 (0.50) LPAR2LPAR3LPAR1
SCHEMBL10880891 0.88 DNM1 (0.50) LPAR2LPAR3LPAR1
SCHEMBL1095622 0.88 DNM1 (0.50) LPAR2LPAR3LPAR1
SCHEMBL2548513 0.88 DNM1 (0.50) LPAR2LPAR3LPAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12594292-B2 Antiviral prodrugs, intermediate-and long-acting formulations and methods THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2026-04-07 US disclosed
US-20250177428-A1 ANTIVIRAL PRODRUGS, INTERMEDIATE-AND LONG-ACTING FORMULATIONS AND METHODS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2025-06-05 US disclosed
WO-2024159117-A1 ANTIVIRAL PRODRUGS, INTERMEDIATE-AND LONG-ACTING FORMULATIONS, AND METHODS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-08-02 WO disclosed
US-20100286151-A1 1-OXA-3-Azaspiro[4,5]Decan--2-One Derivatives For The Treatment Of Eating Disorders BENTLEY JONATHAN 2010-11-11 US disclosed
US-3933733-A Phosphite stabilized polyvinyl chloride containing resins KYODO CHEMICAL COMPANY, LIMITED (JA) 1976-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12594292-B2 Antiviral prodrugs, intermediate-and long-acting formulations and methods ACE2, SARS1, FURIN ALDH1A1 4279/4885CNR1 2852/4885CNR2 1886/4885
US-20250177428-A1 ANTIVIRAL PRODRUGS, INTERMEDIATE-AND LONG-ACTING FORMULATIONS AND METHODS SARS1, ACE2, FURIN ALDH1A1 3768/4885CNR1 1769/4885CNR2 1566/4885
US-20100286151-A1 1-OXA-3-Azaspiro[4,5]Decan--2-One Derivatives For The Treatment Of Eating Disorders NPY5R, NPY1R, NPY4R ALDH1A1 3300/4885CNR1 11/4885CNR2 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.